Cambridge Epigenetix (UK) wants to unlock the power of the Epigenome and become what Illumina is for NGS. And now, it has gotten the €18.9M and a new CEO needed to achieve this.
Cambrige Epigenetix is a Biotech developing epigenetic tools, and was initially founded by Cambridge Enterprise (an incubator of the University of Cambridge) and Syncona Partners – one of the top 15 VCs in Europe.
Now, Epigenetix has raised around €18.9M ($21M) in a series B round, and from very interesting investors. These are GV (formerly Google Ventures) and Sequoia Capital – one of the most prominent VCs in Silicon Valley.
This is another case of conventional Tech investors going for Biotech companies. But why did they choose this particular Biotech?